Subsea 7 S.A. has received notification of transactions in its shares by primary insiders. Please see the attachment for details. This information is pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
Attachment
Subsea 7 S.A. has received notification of transactions in its shares by primary insiders. Please see the attachment for details. This information is pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
Attachment
Please see below information about transactions made under the buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR) for shares to be used in the share-based incentive programmes for employees and management.
Correction: Due to an error in the figure reported under “Total buy-backs under the programme” in the stock market announcement published on 19 August 2026, and in the column “Previously disclosed buy-backs under the programme (accumulated)” in the announcement published on 18 September 2026 regarding the share buy-back programme for employee and management share-based incentive schemes, this corrective stock exchange announcement is being issued. The correct number of shares in the aforementioned announcements was 1,143,847,326 shares. The correct figure as of 19 August 2026 is set out below in this corrective announcement.
Date on which the buy-back programme was announced: 4 February 2026.
The duration of the buy-back programme: 13 February 2026 to 15 January 2027.
Size of the buy-back programme: The total purchase amount under the programme is NOK 1,971,000,000 and the maximum shares to be acquired is 19,600,000 shares, of which up to 7,920,000 shares can be acquired in the period from 13 February 2026 to 15 May 2026, and up to 11,680,000 shares can be acquired in the period from 15 May 2026 to 15 January 2027.
On 15 September 2026, Equinor ASA has purchased a total of 379,361 own shares at the Oslo Stock Exchange at an average price of NOK 419.1253 per share.
Aggregated overview of transactions per day:
| Date | Aggregated volume (number of shares) | Weighted average share price (NOK) | Total transaction value (NOK) |
| 15 September 2026 | 379,361 | 419.1253 | 158,999,793 |
| Previously disclosed buy-backs under the programme (accumulated) | 3,399,081 | 336.5166 | 1,143,847,326 |
| Total buy-backs under the programme | 3,778,442 | 344.8107 | 1,302,847,119 |
Following the completion of the above transactions, Equinor ASA owns a total of 19,798,825 own shares, corresponding to 0.83% of Equinor ASA’s share capital, including shares purchased under the previous buy-back programme for the share-based incentive programmes for employees, and shares purchased under Equinor’s disclosed buy-back programmes which will be used to reduce the issued share capital of the company.
This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
Appendix: A detailed overview of all transactions made under the buy-back programme that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.
Further information from:
Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791
Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584
Attachment
Please see below information about transactions made under the buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR) for shares to be used in the share-based incentive programmes for employees and management.
Correction: Due to an error in the figure reported under “Total buy-backs under the programme” in the stock market announcement published on 19 August 2026, and in the column “Previously disclosed buy-backs under the programme (accumulated)” in the announcement published on 18 September 2026 regarding the share buy-back programme for employee and management share-based incentive schemes, this corrective stock exchange announcement is being issued. The correct number of shares in the aforementioned announcements was 1,143,847,326 shares. The correct figure as of 19 August 2026 is set out below in this corrective announcement.
Date on which the buy-back programme was announced: 4 February 2026.
The duration of the buy-back programme: 13 February 2026 to 15 January 2027.
Size of the buy-back programme: The total purchase amount under the programme is NOK 1,971,000,000 and the maximum shares to be acquired is 19,600,000 shares, of which up to 7,920,000 shares can be acquired in the period from 13 February 2026 to 15 May 2026, and up to 11,680,000 shares can be acquired in the period from 15 May 2026 to 15 January 2027.
On 15 September 2026, Equinor ASA has purchased a total of 379,361 own shares at the Oslo Stock Exchange at an average price of NOK 419.1253 per share.
Aggregated overview of transactions per day:
| Date | Aggregated volume (number of shares) | Weighted average share price (NOK) | Total transaction value (NOK) |
| 15 September 2026 | 379,361 | 419.1253 | 158,999,793 |
| Previously disclosed buy-backs under the programme (accumulated) | 3,399,081 | 336.5166 | 1,143,847,326 |
| Total buy-backs under the programme | 3,778,442 | 344.8107 | 1,302,847,119 |
Following the completion of the above transactions, Equinor ASA owns a total of 19,798,825 own shares, corresponding to 0.83% of Equinor ASA’s share capital, including shares purchased under the previous buy-back programme for the share-based incentive programmes for employees, and shares purchased under Equinor’s disclosed buy-back programmes which will be used to reduce the issued share capital of the company.
This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
Appendix: A detailed overview of all transactions made under the buy-back programme that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.
Further information from:
Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791
Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584
Attachment
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century’s iPSC-derived islet replacement therapy for type 1 diabetes
CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027
PHILADELPHIA, Oct. 02, 2026 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (“Century”, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced the presentation of nonclinical data for CNTY-813, Century’s iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0. Data were presented in an oral presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy.
In a study lasting over eleven months, updated data demonstrated CNTY-813 maintained glycemic control in a diabetic mouse model until CNTY-813’s graft removal. New data further highlighted CNTY-813’s anticipated readiness for clinical testing via demonstration of drug product consistency across five clinical-scale runs, glycemic control in a diabetic mouse model after extended drug product cold storage, and successful engraftment of CNTY-813 via the intended clinical route of administration.
“The data presented at EASD build on the nonclinical package we presented at ADA in June and highlight our continued execution on bringing CNTY-813 into the clinic,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “Following our pre-IND meeting, in which we reached general alignment with FDA on our nonclinical package, Phase 1 manufacturing process and proposed Phase 1/2 trial design, we remain on track to submit the CNTY-813 IND in the fourth quarter of this year with initial clinical data anticipated in the second half of 2027.”
New Nonclinical Data Highlights
Glycemic control sustained until graft removal in diabetic mice
Phase 1 clinical manufacturing process produced consistent product across five clinical-scale batches
Liver portal vein delivery in rats resulted in successful engraftment supporting the planned clinical route of administration
Clinical-scale product remained functional after 96 hours of cold storage, supporting future clinical supply chain
Grant Welstead, Ph.D., Senior Vice President, Head of Research at Century, delivered the presentation, titled “CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC-Derived Islets for Off-the-Shelf Cell Therapies” (Presentation 225), on Friday, October 2, 2026, in Session OP 39, “Beta cells on demand: stem cells to beta cell therapy,” held from 10:00 to 11:00 a.m. Central European Summer Time in Paris Hall. The presentation is available in the Scientific Resources section of the Science page on Century’s website at Events and Presentations | Century Therapeutics.
Upcoming CNTY-813 Milestones
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of iPSC-derived cell therapies with the potential to meaningfully address autoimmune diseases, including T1D, and cancer. Century’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our timing and expectations for regulatory submissions, nonclinical and clinical development, including CNTY-813’s IND submission and expected data readout in the second half of 2027, and our financial resources and expected cash runway, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
For More Information:
Century Therapeutics
Douglas Carr
Senior Vice President, Finance
investor.relations@centurytx.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century’s iPSC-derived islet replacement therapy for type 1 diabetes
CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027
PHILADELPHIA, Oct. 02, 2026 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (“Century”, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced the presentation of nonclinical data for CNTY-813, Century’s iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0. Data were presented in an oral presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy.
In a study lasting over eleven months, updated data demonstrated CNTY-813 maintained glycemic control in a diabetic mouse model until CNTY-813’s graft removal. New data further highlighted CNTY-813’s anticipated readiness for clinical testing via demonstration of drug product consistency across five clinical-scale runs, glycemic control in a diabetic mouse model after extended drug product cold storage, and successful engraftment of CNTY-813 via the intended clinical route of administration.
“The data presented at EASD build on the nonclinical package we presented at ADA in June and highlight our continued execution on bringing CNTY-813 into the clinic,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “Following our pre-IND meeting, in which we reached general alignment with FDA on our nonclinical package, Phase 1 manufacturing process and proposed Phase 1/2 trial design, we remain on track to submit the CNTY-813 IND in the fourth quarter of this year with initial clinical data anticipated in the second half of 2027.”
New Nonclinical Data Highlights
Glycemic control sustained until graft removal in diabetic mice
Phase 1 clinical manufacturing process produced consistent product across five clinical-scale batches
Liver portal vein delivery in rats resulted in successful engraftment supporting the planned clinical route of administration
Clinical-scale product remained functional after 96 hours of cold storage, supporting future clinical supply chain
Grant Welstead, Ph.D., Senior Vice President, Head of Research at Century, delivered the presentation, titled “CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC-Derived Islets for Off-the-Shelf Cell Therapies” (Presentation 225), on Friday, October 2, 2026, in Session OP 39, “Beta cells on demand: stem cells to beta cell therapy,” held from 10:00 to 11:00 a.m. Central European Summer Time in Paris Hall. The presentation is available in the Scientific Resources section of the Science page on Century’s website at Events and Presentations | Century Therapeutics.
Upcoming CNTY-813 Milestones
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of iPSC-derived cell therapies with the potential to meaningfully address autoimmune diseases, including T1D, and cancer. Century’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our timing and expectations for regulatory submissions, nonclinical and clinical development, including CNTY-813’s IND submission and expected data readout in the second half of 2027, and our financial resources and expected cash runway, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
For More Information:
Century Therapeutics
Douglas Carr
Senior Vice President, Finance
investor.relations@centurytx.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
Major Institutional Formulary Win Expands Arbli™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially
Arbli™ Addresses an Approximately $219 Million U.S. Losartan Market Representing Approximately 72 Million Prescriptions Annually
COMMACK, NY, Oct. 02, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL has been added to the formulary of three (3) leading U.S. pediatric academic medical centers and hospitals specializing in the treatment of children with complex and chronic medical conditions.
The formulary additions represent an important commercial milestone for Arbli™ and expands the product’s presence within the institutional and pediatric healthcare market. Arbli™ is a proprietary oral suspension formulation of losartan potassium designed to improve patient access and compliance, particularly among pediatric, geriatric and other patient populations with difficulty swallowing tablets.
Arbli™ addresses a large and established U.S. losartan market representing approximately $219 million in sales and approximately 72 million prescriptions annually (IQVIA MAT Apr 2026). By eliminating the variability and inconvenience associated with pharmacy compounding, Scienture believes that Arbli™ provides healthcare professionals with a consistent, convenient and scalable ready-to-use treatment option.
Arbli™ is indicated for the treatment of hypertension in adults and pediatric patients six years of age and older. Its ready-to-use 10 mg/mL oral suspension provides flexible dosing without the need for extemporaneous pharmacy compounding, attributes that are particularly relevant in pediatric care, where patients may require individualized dosing or have difficulty swallowing conventional tablets.
Narasimhan Mani, President and Co-Chief Executive Officer of Scienture, commented, “The commercial rollout of Arbli™ has continued to gain momentum, with wholesale orders increasing sequentially and adoption expanding across key healthcare channels. These formulary additions represent an important growth milestone in the commercialization of Arbli™ and, importantly, its adoption within the pediatric healthcare setting, where the product provides much needed patient benefits. With the U.S. losartan market representing approximately $219 million in sales annually, even modest market penetration could represent a meaningful commercial opportunity for Arbli™. The opportunity is particularly compelling given Scienture’s high gross margins, providing significant operating leverage as we continue to expand Arbli™’s market penetration. We believe the combination of expanding institutional adoption, increasing wholesale orders and a highly attractive market opportunity provides a strong foundation for continued growth.”
“We believe this is just the beginning of the opportunity for Arbli™ within the pediatric hospital market,” added Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture. “We believe the addition of Arbli™ by leading pediatric academic medical centers can help support our efforts to expand adoption across other institutions. We remain focused on building broader hospital and institutional access while continuing to expand payer coverage, pharmacy availability and distribution nationwide.”
The new formulary placements build upon Scienture’s broader commercialization strategy for Arbli™, which is focused on expanding commercial and government payer coverage, pharmacy availability, institutional adoption and distribution access. The Company intends to continue pursuing hospital and institutional formulary opportunities, including within pediatric healthcare settings, as it works to broaden Arbli™ adoption and increase patient access nationwide.
About Arbli™
Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:
IMPORTANT SAFETY INFORMATION
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About Hypertension
Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, such as Arbli™, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on The Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Email: IR@Scienture.com
Major Institutional Formulary Win Expands Arbli™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially
Arbli™ Addresses an Approximately $219 Million U.S. Losartan Market Representing Approximately 72 Million Prescriptions Annually
COMMACK, NY, Oct. 02, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL has been added to the formulary of three (3) leading U.S. pediatric academic medical centers and hospitals specializing in the treatment of children with complex and chronic medical conditions.
The formulary additions represent an important commercial milestone for Arbli™ and expands the product’s presence within the institutional and pediatric healthcare market. Arbli™ is a proprietary oral suspension formulation of losartan potassium designed to improve patient access and compliance, particularly among pediatric, geriatric and other patient populations with difficulty swallowing tablets.
Arbli™ addresses a large and established U.S. losartan market representing approximately $219 million in sales and approximately 72 million prescriptions annually (IQVIA MAT Apr 2026). By eliminating the variability and inconvenience associated with pharmacy compounding, Scienture believes that Arbli™ provides healthcare professionals with a consistent, convenient and scalable ready-to-use treatment option.
Arbli™ is indicated for the treatment of hypertension in adults and pediatric patients six years of age and older. Its ready-to-use 10 mg/mL oral suspension provides flexible dosing without the need for extemporaneous pharmacy compounding, attributes that are particularly relevant in pediatric care, where patients may require individualized dosing or have difficulty swallowing conventional tablets.
Narasimhan Mani, President and Co-Chief Executive Officer of Scienture, commented, “The commercial rollout of Arbli™ has continued to gain momentum, with wholesale orders increasing sequentially and adoption expanding across key healthcare channels. These formulary additions represent an important growth milestone in the commercialization of Arbli™ and, importantly, its adoption within the pediatric healthcare setting, where the product provides much needed patient benefits. With the U.S. losartan market representing approximately $219 million in sales annually, even modest market penetration could represent a meaningful commercial opportunity for Arbli™. The opportunity is particularly compelling given Scienture’s high gross margins, providing significant operating leverage as we continue to expand Arbli™’s market penetration. We believe the combination of expanding institutional adoption, increasing wholesale orders and a highly attractive market opportunity provides a strong foundation for continued growth.”
“We believe this is just the beginning of the opportunity for Arbli™ within the pediatric hospital market,” added Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture. “We believe the addition of Arbli™ by leading pediatric academic medical centers can help support our efforts to expand adoption across other institutions. We remain focused on building broader hospital and institutional access while continuing to expand payer coverage, pharmacy availability and distribution nationwide.”
The new formulary placements build upon Scienture’s broader commercialization strategy for Arbli™, which is focused on expanding commercial and government payer coverage, pharmacy availability, institutional adoption and distribution access. The Company intends to continue pursuing hospital and institutional formulary opportunities, including within pediatric healthcare settings, as it works to broaden Arbli™ adoption and increase patient access nationwide.
About Arbli™
Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:
IMPORTANT SAFETY INFORMATION
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About Hypertension
Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, such as Arbli™, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on The Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Email: IR@Scienture.com
Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall
Patent reinforces Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies
THE WOODLANDS, TX, Oct. 02, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 3,183,802, titled, “Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within and/or Through a Lumen Wall.” The Company’s growing global intellectual property portfolio now includes 112 issued or pending patent applications worldwide, with the newly issued patent further strengthening its intellectual property position across multiple nerve-targeted therapies and denervation applications.
The newly issued patent protects the Company’s catheter-based transvascular intervention technologies designed to access tissue beyond the vessel wall and guide, optimize and validate therapy delivery using real-time physiological feedback.
Corresponding patents covering related inventions have previously been issued in the United States and Europe, reinforcing Autonomix’s intellectual property position across major commercial markets.
“We believe the future of nerve-targeted therapy lies not only in identifying the appropriate neural target, but in enabling physicians to precisely access that target, deliver therapy with objective physiological feedback, and determine whether the intended therapeutic effect has been achieved,” commented Brad Hauser, Chief Executive Officer of Autonomix Medical. “This patent strengthens protection around the core technologies that enable catheter-based transvascular intervention, reinforcing the differentiated capabilities of our platform and supporting our long-term strategy to advance next-generation neuromodulation technologies across multiple clinical applications.”
The newly granted Canadian patent covers catheter-based transvascular (intraluminal) tools and systems designed to operate from within a bodily lumen, where deployable probes penetrate into and/or through a lumen wall to access tissue and nerves located outside the vessel. The patent covers multi-site electrophysiological sensing, incorporating sensing at a target site, secondary site, and reference site to improve, for example, signal quality and procedural confidence. The patent also encompasses methods for assessing procedural completion based on electrophysiological signal processing, including detection of changes in neural activity patterns to assess treatment effect and procedural outcomes.
In addition, the patent includes closed-loop control capabilities that enable systems to adjust stimulation or therapeutic energy delivery in real time based on live electrophysiological feedback. This supports adaptive neuromodulation and more data-driven procedural workflows. The patent further covers a broad range of electrophysiological signal types and therapeutic modalities, with potential applicability across multiple nerve-targeted indications. It also includes system-level claims covering control units configured to evaluate, guide, and optimize procedures using real-time electrophysiological data.
Autonomix has built a comprehensive intellectual property portfolio designed to provide broad, area-by-area protection across the body, encompassing core platforms for nerve mapping, signal processing, and controlled micro-ablation, along with application-specific innovations across multiple organ systems. With issued patents in the United States, Canada, Europe, and other key international jurisdictions, and expirations extending into the late 2030s, the portfolio is structured to support multi-organ platform scalability and expansion into diverse clinical indications.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, expectations regarding the potential effectiveness and clinical benefits of Autonomix’s nerve-targeted treatments for pancreatic cancer pain and other conditions, the Company’s planned U.S. clinical study, anticipated physician adoption, potential strategic partnerships, reimbursement discussions, the scope and commercial value of the Company’s intellectual property portfolio, and the potential applicability of the Company’s platform technology across multiple clinical indications and organ systems.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall
Patent reinforces Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies
THE WOODLANDS, TX, Oct. 02, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 3,183,802, titled, “Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within and/or Through a Lumen Wall.” The Company’s growing global intellectual property portfolio now includes 112 issued or pending patent applications worldwide, with the newly issued patent further strengthening its intellectual property position across multiple nerve-targeted therapies and denervation applications.
The newly issued patent protects the Company’s catheter-based transvascular intervention technologies designed to access tissue beyond the vessel wall and guide, optimize and validate therapy delivery using real-time physiological feedback.
Corresponding patents covering related inventions have previously been issued in the United States and Europe, reinforcing Autonomix’s intellectual property position across major commercial markets.
“We believe the future of nerve-targeted therapy lies not only in identifying the appropriate neural target, but in enabling physicians to precisely access that target, deliver therapy with objective physiological feedback, and determine whether the intended therapeutic effect has been achieved,” commented Brad Hauser, Chief Executive Officer of Autonomix Medical. “This patent strengthens protection around the core technologies that enable catheter-based transvascular intervention, reinforcing the differentiated capabilities of our platform and supporting our long-term strategy to advance next-generation neuromodulation technologies across multiple clinical applications.”
The newly granted Canadian patent covers catheter-based transvascular (intraluminal) tools and systems designed to operate from within a bodily lumen, where deployable probes penetrate into and/or through a lumen wall to access tissue and nerves located outside the vessel. The patent covers multi-site electrophysiological sensing, incorporating sensing at a target site, secondary site, and reference site to improve, for example, signal quality and procedural confidence. The patent also encompasses methods for assessing procedural completion based on electrophysiological signal processing, including detection of changes in neural activity patterns to assess treatment effect and procedural outcomes.
In addition, the patent includes closed-loop control capabilities that enable systems to adjust stimulation or therapeutic energy delivery in real time based on live electrophysiological feedback. This supports adaptive neuromodulation and more data-driven procedural workflows. The patent further covers a broad range of electrophysiological signal types and therapeutic modalities, with potential applicability across multiple nerve-targeted indications. It also includes system-level claims covering control units configured to evaluate, guide, and optimize procedures using real-time electrophysiological data.
Autonomix has built a comprehensive intellectual property portfolio designed to provide broad, area-by-area protection across the body, encompassing core platforms for nerve mapping, signal processing, and controlled micro-ablation, along with application-specific innovations across multiple organ systems. With issued patents in the United States, Canada, Europe, and other key international jurisdictions, and expirations extending into the late 2030s, the portfolio is structured to support multi-organ platform scalability and expansion into diverse clinical indications.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, expectations regarding the potential effectiveness and clinical benefits of Autonomix’s nerve-targeted treatments for pancreatic cancer pain and other conditions, the Company’s planned U.S. clinical study, anticipated physician adoption, potential strategic partnerships, reimbursement discussions, the scope and commercial value of the Company’s intellectual property portfolio, and the potential applicability of the Company’s platform technology across multiple clinical indications and organ systems.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
